drugset / Trial / NCT00773240

A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment

NCT00773240

Phase 3 Completed 276 enrolled ALK-Abelló A/S
RandomizedParallel-groupTriple-blindTreatment

Summary

The study assess the pharmacodynamic effect and the tolerability of Grazax treatment initiated in the grass pollen season in subjects with seasonal grass pollen induced rhinoconjunctivitis

Timeline

Start
2008-04
Primary completion
2008-10
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Grazax Other / unclassified 75000 unknown Oral